BETA: Please send your feedback!
Sorrento Therapeutics
SRNE:NAS
Biotechnology
$0
SMALL cap
$3.52
(0.26%)
0.41%
since start of 2019
-1.57
- —
- 1
- 2
- 3
- 4
- 5
About
Biotechnology
Founded 2006
Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. The company was founded by Henry H. Ji in 2006 and is headquartered in San Diego, CA.
website
Headquarters
Executives
| Name | Title | Gender |
| George K. Ng | Chief Administrative Officer & Executive VP | Male |
| William S. Marth, MBA | Chairman | Male |
| Jerome B. Zeldis, MD, PhD | Chief Medical Officer | Male |
| Henry H. Ji, PhD | President, Chief Executive Officer & Director | Male |
| Kevin M. Herde, CPA | Chief Financial Officer & Executive Vice President | Male |
| Jeffrey Su, Phd | Chief Operating Officer & Executive Vice President | Male |
Mindful Investing Summary
- —
- 1
- 2
- 3
- 4
- 5
Sorrento Therapeutics - Competitors and Related Companies
How Sorrento Therapeutics stacks up to its peers in the Biotechnology industry or with competing business segments.
Sorrento Therapeutics
SRNE:NAS
Biotechnology
$0
SMALL cap
$3.52
(0.26%)
0.41%
since start of 2019
-1.57
Karyopharm Therapeutics
KPTI:NAS
Biotechnology
$1.02bn
SMALL cap
$16.29
(-1.16%)
0.64%
since start of 2019
-4.76
Synergy Pharmaceuticals
SGYP:NAS
Pharmaceuticals: Other
$0
SMALL cap
$0.03
(0.00%)
-0.86%
since start of 2019
-0.05
Exelixis
EXEL:NAS
Biotechnology
$5.27bn
MID cap
$17.36
(0.21%)
-0.12%
since start of 2019
8.52